SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-067041
Filing Date
2023-08-14
Accepted
2023-08-14 16:11:07
Documents
56
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0623_tffpharma.htm   iXBRL 10-Q 712993
2 CERTIFICATION f10q0623ex31-1_tffpharma.htm EX-31.1 10301
3 CERTIFICATION f10q0623ex31-2_tffpharma.htm EX-31.2 10558
4 CERTIFICATION f10q0623ex32-1_tffpharma.htm EX-32.1 4980
5 GRAPHIC image_001.jpg GRAPHIC 2933
  Complete submission text file 0001213900-23-067041.txt   3415551

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20230630.xsd EX-101.SCH 44595
7 XBRL CALCULATION FILE tffp-20230630_cal.xml EX-101.CAL 28295
8 XBRL DEFINITION FILE tffp-20230630_def.xml EX-101.DEF 162941
9 XBRL LABEL FILE tffp-20230630_lab.xml EX-101.LAB 348119
10 XBRL PRESENTATION FILE tffp-20230630_pre.xml EX-101.PRE 174752
50 EXTRACTED XBRL INSTANCE DOCUMENT f10q0623_tffpharma_htm.xml XML 286383
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 231170185
SIC: 2834 Pharmaceutical Preparations